TORONTO, ONTARIO--(Marketwired - July 16, 2014) - Easton Pharmaceuticals Inc. (OTC: EAPH) - Announces It is scheduled at the end of July to participate with Amfil Technologies Inc. in the introduction of the first mPACT-Grozone 60™ unit.
As previously announced, mPACT-Grozone 60™ unit is being built for one of Colorado's Premier Medical Marijuana Organizations with development under way for one of the largest indoor cultivation facilities in Colorado and boasts more than 200,000 square feet of hydroponic growing area. Easton Pharmaceuticals recently announced its agreement to invest and acquire an ownership interest in AMFIL Technologies Inc. and the mPACT-Grozone Antimicrobial Systems Line of Products. The Grozone product line, which includes the mPACT 60 unit, can be customized to fit the needs of small, medium and large medical marijuana growing facilities as well as other types of industries and applications. Once the unit's efficacy is validated at one location, the necessity for additional integrated units throughout the cultivation areas should be secured.
Amfil Technologies Inc. has informed Easton Pharmaceuticals that it is in early stage discussions with other large, reputable facilities in Canada and the United States and is moving towards and has high expectations towards introducing and integrating the units and technology into as many grow facilities as possible.
As an increased number of medical marijuana grow facilities utilize the Grozone system and positive feedback spreads, the brand has the potential to not only be a must-have for growers, but could become an industry standard at a time when quality control conditions and regulations for all grow facilities and their products are becoming more stringent and scrutinized.
The number of reliable, capable and reputable antimicrobial systems catering to the size and capacity of the larger grow facilities are limited. While ozone satisfies the antimicrobial needs of medical marijuana grow environment, it is not a new technology. The Grozone 60 is thought to be a state of the art, one of a kind growers' solution utilizing multiple ozone technologies and is thought to be superior and unlike any other ozone product in the industry. Easton Pharmaceuticals will be viewing the unit before it is shipped to Colorado for installation by the end of the month.
Additional information regarding the Grozone technology and specifically the mPACT-Grozone 60 Antimicrobial System, including pictures and videos of the finished product and facility installation where possible will be forthcoming. Easton Pharmaceuticals is very excited about the unit's possibilities and technology related to the overall medical marijuana industry / legal grow processing facilities and potentially other industries. Additional news and more in depth updates are expected to be provided shortly.
In other developments, Additional more detailed updates on the MMPR Canadian grow-op license is expected to be provided shortly as well as positive developments with its "Viorra" product initiative through the efforts of BMV Medica S.A. In addition, Easton has retaining new corporate office space which will be made available by the end of this month.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical / product and services company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has also entered other potentially lucrative industries such as the medical marijuana and services industry. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions.
For More Information Visit:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.